Cowen Maintains Bullish View on Amgen (AMGN) Following Panel Repatha In Familial Hypercholesterolemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
FDA Panel Points to Narrower Label for Amgen's (AMGN) Repatha, Nomura Notes
June 11, 2015 8:31 AM EDTNomura Securities analyst M. Ian Somaiya maintained his Buy rating and $182 price target on Amgen (NASDAQ: AMGN) following FDA panel recommendation for Repatha but notes commentary points to a narrower label.
Somaiya commented, "We believe the recent FDA Advisory Committee panels... More
Amgen (AMGN) Bullish Stance Reiterated at Jefferies Following Repatha Panel Backing
June 11, 2015 6:43 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and $195 price target on Amgen (NASDAQ: AMGN) after an FDA panel recommended approval of Repatha, as expected.
Yang commented, "Positive panel votes were widely expected (11-4 in favor for non-HoFH high-risk pts;... More
UPDATE: Amgen (AMGN) Wins FDA Panel Backing for Repatha
June 10, 2015 3:57 PM EDT(Updated - June 10, 2015 4:26 PM EDT)
An FDA panel voted 11-4 to back Amgen's (NASDAQ: AMGN) Repatha in some patients. The panel also backed the drug for HoFH with a vote of 15-0.
Repatha is an investigational fully human monoclonal antibody that inhibits... More
